Kiora Pharmaceuticals reports FY2022 net loss of $13.6M; clinical milestones on track for 2023

KIORA PHARMACEUTICALS INC

Net loss of $13.6M for FY2022, compared to $13.8M in FY2021; Q4 net loss $2.5M.
Cash and equivalents $6.0M at Dec 31, 2022, plus $1.4M in R&D tax receivables.
KIO-301 Phase 1b ABACUS trial enrollment ongoing; initial results at ARVO April 2023, topline by year-end.
KIO-201 Phase 2 PCED study topline results at ARVO; mean defect size reduction 90% (p<0.003).
KIO-101 Phase 2 trial initiation planned for Q2 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

KIORA PHARMACEUTICALS INC reported financial results for the fiscal year and fourth quarter ended December 31, 2022.

Period: the fiscal year and fourth quarter ended December 31, 2022
Result: reported results

Exact text from the filing

On March 23, 2023, Kiora Pharmaceuticals, Inc. (the “Company”) issued a press release announcing financial results for the fiscal year and fourth quarter ended December 31, 2022 and an update on clinical development progress.

View on SEC.gov

Browse all earnings releases →

KIORA PHARMACEUTICALS INC filing history →

Source: SEC EDGAR

accession 0001372514-23-000051

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.